false
0000832489
0000832489
2026-11-13
2026-11-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 13, 2026
GEOVAX LABS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-39563
|
87-0455038
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File No.)
|
(IRS Employer Identification No.)
|
1955 Lake Park Drive, Suite 300
Smyrna, Georgia 30080
(Address of principal executive offices) (Zip code)
(678) 384-7220
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions.
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.001 per share
|
GOVX
|
The Nasdaq Capital Market
|
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial reporting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Financial Officer
On November 13, 2026, Mark W. Reynolds resigned as Chief Financial Officer and Corporate Secretary of GeoVax Labs, Inc. (the “Company”), and from all other officer positions with the Company and its subsidiaries, effective as of 5:00 p.m. Eastern Time on November 13, 2026. Mr. Reynolds also served as the Company’s principal financial officer and principal accounting officer.
Appointment of Interim Chief Financial Officer
On November 14, 2026, the Board of Directors (the “Board”) of the Company appointed Anna Skowron as Chief Financial Officer of the Company, effective as of November 16, 2026. In this role, Ms. Skowron will also serve as the Company’s principal financial officer and principal accounting officer.
Ms. Skowron, 39, has served as a Director of BPC Consulting Ltd., an Ontario, Canada corporation that provides chief financial officer, accounting, financial reporting and other consulting services to public and private companies, since September 2025. Since March 7, 2025, she has served as Interim Chief Financial Officer of GridAI Technologies Corp.; since February 9, 2026, she has served as Fractional Chief Financial Officer of Powell Max Limited; and since August 2026, she has served as Fractional Chief Financial Officer of BioRestorative Therapies, Inc. From 2020 through June 2026, Ms. Skowron served as Principal of Skowron Accounting Professional Corporation, where she provided chief financial officer, accounting, financial reporting, mergers and acquisitions advisory and capital markets consulting services to public and private companies across a range of industries. During this period, she advised on financings and supported strategic transactions. Ms. Skowron holds a Bachelor of Commerce degree, with a Specialist in Accounting and a Major in Economics, from the University of Toronto.
In connection with Ms. Skowron’s appointment, the Company entered into a CFO Consulting Agreement, dated November 16, 2026 (the “CFO Consulting Agreement”), with BPC Consulting Ltd. (“BPC”), which has designated Ms. Skowron to perform the services thereunder as a non-employee officer of the Company. Ms. Skowron serves on a fractional basis. Under the CFO Consulting Agreement, Ms. Skowron oversees the Company’s accounting and financial reporting, including the preparation of the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”), and reports to the Company’s Chief Executive Officer and the Chairman of the Audit Committee. The Company will pay BPC $10,000 per month, plus applicable taxes, payable on the first day of each month. BPC is eligible to receive a performance-based bonus upon the successful completion of the Company’s annual report on Form 10-K and related year-end audit, in an amount and on terms to be mutually agreed in writing prior to commencement of the year-end audit, and is eligible to participate in the Company’s compensation, bonus incentive and equity-based compensation plans on substantially the same terms as are offered to the Company’s management and executives. The Company will reimburse BPC for reasonable business expenses and will indemnify Ms. Skowron in her capacity as Chief Financial Officer to the fullest extent permitted under the General Corporation Law of the State of Delaware (the “DGCL”). The engagement commenced on November 16, 2026, and continues until terminated. Either party may terminate the CFO Consulting Agreement on 90 days’ prior written notice. If the Company terminates the agreement without giving that notice, it will pay BPC the fees that would have been payable during the notice period, based on the average monthly fees invoiced by BPC during the three months before termination.
The foregoing description of the CFO Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the CFO Consulting Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Other than the CFO Consulting Agreement, there are no arrangements or understandings between Ms. Skowron and any other person pursuant to which she was appointed as an officer of the Company. There are no family relationships between Ms. Skowron and any director or executive officer of the Company, and there are no transactions in which Ms. Skowron has an interest requiring disclosure under Item 404(a) of Regulation S-K (other than the CFO Consulting Agreement).
Consulting Agreement with Interim Chief Executive Officer
As previously reported in the Company’s Current Report on Form 8-K filed with the SEC on November 9, 2026, the Board appointed Tyler O’Brien as Interim Chief Executive Officer and Chairman of the Board. On November 16, 2026, the Company entered into a Consulting Agreement with Mr. O’Brien, effective as of November 5, 2026 (the “O’Brien Consulting Agreement”), pursuant to which Mr. O’Brien serves as the Company’s Chief Executive Officer as a non-employee consultant. Mr. O’Brien serves on an interim basis, until a permanent principal executive officer is appointed or designated. The Company pays Mr. O’Brien $15,000 per month, payable on the first day of each month. The monthly rate is subject to periodic review and adjustment by the Board or its Compensation Committee, but may not be reduced without Mr. O’Brien’s prior written consent. Mr. O’Brien is eligible to participate in the Company’s incentive compensation, bonus and equity-based compensation plans on substantially the same terms as are offered to the Company’s management and executives, and any incentive-based compensation is subject to the Company’s compensation recovery policy adopted pursuant to Rule 10D-1 under the Exchange Act and Nasdaq Listing Rule 5608. The Company will reimburse Mr. O’Brien’s reasonable business expenses and will indemnify him in his capacity as an officer or director to the fullest extent permitted under the DGCL. Either party may terminate the O’Brien Consulting Agreement on 90 days’ prior written notice. If the Company terminates the agreement without giving that notice, it will pay Mr. O’Brien the fees that would have been payable during the notice period, based on the monthly compensation rate then in effect. Mr. O’Brien has waived all claims under any prior agreement with the Company, other than his rights to indemnification, advancement of expenses and exculpation as a director or officer, and any equity awards previously granted to him.
The foregoing description of the O’Brien Consulting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the O’Brien Consulting Agreement, a copy of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference.
Termination of Chief Medical Officer
On November 17, 2026, the Company terminated Kelly T. McKee, M.D., as the Company’s Chief Medical Officer, effective immediately.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
10.1*
|
CFO Consulting Agreement, dated as of November 16, 2026, between GeoVax Labs, Inc. and BPC Consulting Ltd.
|
|
10.2*
|
Consulting Agreement, dated as of November 16, 2026, between GeoVax Labs, Inc. and Tyler O’Brien.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
* Indicates management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 19, 2026
|
|
GEOVAX LABS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Tyler O’Brien
|
|
|
|
|
Tyler O’Brien
|
|
|
|
|
Interim Chief Executive Officer
|
|